[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540317":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":14,"collaborators":7,"id":16,"slug":17,"hasResults":18,"nctId":19,"briefTitle":20,"officialTitle":20,"acronym":7,"eligibilityCriteria":21,"healthyVolunteers":18,"sex":22,"minAge":23,"maxAge":24,"enrollmentInfo":25,"targetDuration":28,"studyType":29,"phases":7,"briefSummary":30,"conditions":31,"keywords":35,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":7},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"zhentong wei, doctor","CONTACT","15804300686","zhentongwei2009@163.com",{"type":15,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100540317","to-explore-the-feasibility-of-dynamic-changes-of-tcr-diversity-in-peripheral-blood-in-monitoring-recurrence-and-evaluating-prognosis-of-epithelial-ovarian-cancer-100540317",false,"NCT06315270","To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer","Inclusion Criteria:\n\n* Newly diagnosed patients with advanced EOC, 18-75 years of age: including patients with preoperative assessment of stage III-IV EOC, who underwent initial tumour cytoreduction and 6-8 courses of postoperative chemotherapy with paclitaxel + carboplatin\u002Fdocetaxel + carboplatin;\n* Eastern Cooperative Oncology Group (ECOG) physical strength status (PS) score of 0 or 1;\n* Cooperation in the treatment process by providing clinicopathological data and imaging data required for the study process;\n* Cooperate with follow-up visits and collection of node blood for clinical efficacy assessment, and agree to use the test data for subsequent research and product development.\n* The initial and follow-up treatment processes are in accordance with NCCN guidelines;\n\nExclusion Criteria:\n\n* Neoadjuvant chemotherapy patients;\n* Splenectomy patients;\n* Patients with contraindications to radiotherapy;\n* Any other patients who, in the judgement of the investigator, may have poor compliance with the procedures and requirements of the study;\n* Unacceptable or unavailable means of assessing specified efficacy such as imaging;\n* Vaccination within 2 months; antibiotics for infection within 2 weeks; history of blood transfusion within 2 weeks;\n* Long-term use of recombinant human erythropoietin, recombinant human interleukin, Ricodin tablets and other drugs affecting the composition of blood cells;\n* Severe organ dysfunction;\n* Infectious diseases such as immunodeficiency syndrome, active tuberculosis, HIV infection, and other infectious diseases not suitable for participation;\n* Pre-cancerous diseases of the blood, such as myelodysplastic syndromes;\n* Have received immunosuppressive therapy within 2 weeks;\n* Suffering from blood clotting disorders.","FEMALE","18 Years","75 Years",{"count":26,"type":27},100,"ESTIMATED","5 Years","OBSERVATIONAL","This project proposes to elucidate the functional impact of T cells in cancer progression and treatment through a comprehensive TCR profiling study and a longitudinal cohort study in patients with advanced epithelial ovarian cancer. Our findings aim to provide clinical insights for monitoring treatment response in a non-invasive way and demonstrate the association of TCR diversity with clinical outcomes and the potential role of TCR profiling in cancer prognosis.",[32,33,34],"Epithelial Ovarian Cancer","Stage III Ovarian Cancer","Stage IV Ovarian Cancer",[36,37],"TCR","Immunological monitoring","NOT_YET_RECRUITING","2024-03-29",{"date":41,"type":42},"2024-04-01","ACTUAL",{"date":44,"type":27},"2024-03-20",{"date":46,"type":27},"2029-03-20",{"name":5,"class":6}]